Full
Outline
To explore the efficacy of Bufei Yishen Qutan Naqi method combined with Budigefu（budesonide，glycopyrronium bromide and formoterol fumarate）in the treatment of patients with stable chronic obstructive pulmonary disease（COPD）of Yang deficiency and phlegm obstruction type.
A total of 95 patients with stable COPD were enrolled as the research subjects and were classified into control group（48 cases）and experimental group（47 cases）according to the random number table method. Both groups were given the basic treatment，and the control group was treated with Budigefu while the experimental group was given Bufei Yishen Qutan Naqi method＋Budigefu. Both groups were treated for 3 months. The TCM syndromes scores，pulmonary function［forced expiratory volume in the first second as a percentage of predicted value（FEVl%pred），FEVl/forced vital capacity（FVC），maximum mid-expiratory flow（MMEF），peak flow rate（PEF）］，airway remodeling indicators［matrix metalloproteinase（MMP）-9，tissue inhibitor of metalloproteinase（TIMP）-1，MMP-9/TIMP-1］，inflammatory indicators［interleukin（IL）-8，tumor necrosis factor（TNF）-α］，vascular endothelial function indicators［endothelin（ET），nitric oxide（NO）］and activity ability［six-minute walking test（6 MWT），modified Medical Research Council（mMRC）］were compared between both groups before and after treatment.
After 3 months of treatment，the scores of TCM syndromes，levels of serum IL-8，TNF-α，ET，MMP-9 and MMP-9/TIMP-1 were decreased in the two groups，and the decreases of the above indicators in the experimental group were higher than those in the control group（P<0.05）. The levels of FEV1%pred，FEV1/FVC，MMEF，PEF，serum NO and TIMP-1 and the distance of 6MWT were increased in both groups，and the increases were higher in the experimental group（P<0.05）.
Bufei Yishen Qutan Naqi method combined with Budigefu can effectively improve the endothelial function，reduce the airway remodeling，inhibit the inflammatory response，and then relieve the clinical symptoms，improve the pulmonary function，and promote the recovery of life activity ability in the treatment of stable COPD of Yang deficiency and phlegm obstruction type.
32
14
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
